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Abstract
Introduction Prenatal levels of mitogens may influence the
lifetime breast cancer risk by driving stem cell proliferation and
increasing the number of target cells, and thereby increasing the
chance of mutation events that initiate oncogenesis. We
examined in umbilical cord blood the correlation of potential
breast epithelial mitogens, including hormones and growth
factors, with hematopoietic stem cell concentrations serving as
surrogates of overall stem cell potential.
Methods We analyzed cord blood samples from 289 deliveries.
Levels of hormones and growth factors were correlated with
concentrations of stem cell and progenitor populations (CD34+
cells, CD34+CD38- cells, CD34+c-kit+ cells, and granulocyte–
macrophage colony-forming units). Changes in stem cell
concentration associated with each standard deviation change
in mitogens and the associated 95% confidence intervals were
calculated from multiple regression analysis.
Results Cord blood plasma levels of insulin-like growth factor-1
(IGF-1) were strongly correlated with all the hematopoietic stem
and progenitor concentrations examined (one standard-
deviation increase in IGF-1 being associated with a 15–19%
increase in stem/progenitor concentrations, all P < 0.02). Estriol
and insulin-like growth factor binding protein-3 levels were
positively and significantly correlated with some of these cell
populations. Sex hormone-binding globulin levels were
negatively correlated with these stem/progenitor pools. These
relationships were stronger in Caucasians and Hispanics and
were weaker or not present in Asian-Americans and African-
Americans.
Conclusion Our data support the concept that in utero
mitogens may drive the expansion of stem cell populations. The
correlations with IGF-1 and estrogen are noteworthy, as both
are crucial for mammary gland development.
Introduction
It has been hypothesized that the in utero environment and
perinatal factors may influence breast cancer risk of the off-
spring later in life [1]. Epidemiological and experimental data
have provided support to this hypothesis using surrogate indi-
cators of the in utero and perinatal environment. Birth weight
has thus been positively correlated with lifetime risk of breast
cancer [2], as well as other cancers [3-5]; in addition, the off-
spring of preeclamptic pregnancies, probably reflecting an
ERα = estrogen receptor alpha; FITC = fluorescein isothiocyanate; FBS = fetal bovine serum; GM-CSF = granulocyte–macrophage colony-forming 
units; IGF-1 = insulin-like growth factor-1; IGFBP-3 = insulin-like growth factor binding protein-3; MNC = mononuclear cell; PBS = phosphate-buff-
ered saline; SHBG = sex hormone-binding globulin.
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abnormal endocrine environment, have a markedly reduced
lifetime risk of breast cancer [6].
A stem cell burden theory has been invoked to explain how in
utero and perinatal factors might impact lifetime breast cancer
risk [7-10]. The tenets of this theory include the following.
Firstly, the breast cancer risk is related to the pool size of
breast stem cells, which may be determined in utero or early
in life. A second tenet is that individuals with relatively elevated
in utero/perinatal levels of growth factors (for example, insulin-
like growth factor-1 (IGF-1)) and hormones (for example,
estrogens) that act as mammary epithelial cell mitogens will
have relatively large and mitotically active pools of breast stem
cells. This would increase the probability that oncogenic muta-
tions will occur in one of these cells. Thirdly, in the presence
of elevated levels of mitogens, such individuals might also
have a general increase in various stem cell pools and possibly
birth weights. When first proposed, this concept was highly
speculative [1,7]. Since that first proposal, however, the exist-
ence of stem-like, multipotential breast epithelial cells in both
mice [11,12] and humans [13,14] has been established. Addi-
tionally, there is evidence for malignant breast 'stem' cells with
some properties of normal breast stem/progenitor cells, sug-
gesting that the former may be derived from the latter [15].
Preliminary and indirect support for this stem cell-based
hypothesis came from a pilot study on 40 umbilical cord blood
samples from infants delivered in the Worcester, MA, area
[16]. In that study, cord blood plasma levels of several key sex
hormones, including estradiol, estriol, testosterone and pro-
gesterone, the sex hormone-binding globulin (SHBG) and cer-
tain growth factors including prolactin and IGF-1, as well as
one of the major IGF-1 binding proteins, insulin-like growth
factor binding protein-3 (IGFBP-3), were assayed to deter-
mine whether they correlated with the density of cord blood-
derived hematopoietic stem cell and progenitor cell popula-
tions, serving as surrogates for overall stem cell potential.
Such populations included cord blood CD34+ cells, repre-
senting progenitors of hematopoietic cells, endothelial cells
and possibly other cell types, CD34+CD38- cells, represent-
ing primitive hematopoietic stem/progenitor cells, and granu-
locyte–macrophage colony-forming units (GM-CFU),
representing a functional measure of multipotential, prolifera-
tive hematopoietic precursor cells [17]. There was indication
that cord blood plasma levels of IGF-1, and to a lesser extent
estriol and testosterone, are positively correlated with the den-
sity of cord blood CD34+cells, CD34+CD38- cells, and GM-
CFU [16].
The current study was carried out to determine whether the
correlations between cord blood growth factors and hormone
levels and stem cell populations are robust in a larger, more
broadly based, population sampling. A total of 289 cord blood
samples incorporating 40 samples from the pilot study and
249 samples from the Tufts–New England Medical Center,
covering a more racially/ethnically diverse area, were analyzed.
Patients and methods
Study subjects
Study subjects were recruited from one of two sources: par-
ticipants in the Worcester, MA-based American Red Cross
cord blood program, in which hematopoietic stem cells from
umbilical cord blood were collected for transplantation; and
pregnant women delivering at the Tufts–New England Medical
Center in Boston, MA. In all instances, eligible participants
were 18 years of age or older, bearing a single fetus with no
anomalies by sonography and with no indication of umbilical
cord prolapse or amniotic fluid embolism, and were negative
for human immunodeficiency, hepatitis B, and hepatitis C
viruses. Each participant signed a consent form approved by
the human subjects committee of the institution where deliver-
ies occurred.
Umbilical cord blood samples were obtained from full-term
(gestational age ≥37 weeks) infants. Prior to collection, the
cord was cleaned with alcohol and Betadine. Umbilical cord
blood was drained from the umbilical vein using a 16-gauge
needle and was collected in a collection bag containing 35 ml
citrate–phosphate–dextrose anticoagulant (Baxter Health
Care, Deerfield, IL, USA). Samples were generally obtained
with the placenta in utero; however, cord blood was collected
after delivery of the placenta in the case of childbirths requiring
cesarean section.
Women consenting to the study were asked to provide their
age, race, education, number of prior pregnancies and live
births, pregnancy complications, and family history. Informa-
tion on the birth weight and gestational age of the infant was
also recorded. The study protocol was approved by the insti-
tutional review boards of the American Red Cross, the Univer-
sity of Massachusetts Medical School, the University of
Massachusetts/Memorial Health Care System, St Vincent's
Hospital, and the Tufts–New England Medical Center.
Processing of umbilical cord blood samples
Cord blood samples were kept at room temperature after col-
lection, during transportation, and at the initial processing,
always within 24 hours of the time of collection. The total vol-
ume of the cord blood samples was measured, and a com-
plete blood count with automated differential was performed
on an aliquot of the blood using a model ACT-diff Coulter
Counter (Beckman Coulter, Hialeah, FL, USA). Each cord
blood sample was centrifuged for 30 min at 400 × g in a Sor-
vall Legend RT (Kendro Laboratory Products, Osterode, Ger-
many centrifuge at room temperature. The cord blood plasma
was removed, placed into 2 ml aliquots, and stored at -70°C
until analysis. The buffy coat was harvested, diluted 1:1 with
Iscove's modified Dulbecco's medium containing 2% fetal
bovine serum (FBS) (Stem Cell Technologies, Vancouver, BC,
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Canada), then layered onto Ficoll-Paque PLUS® and centri-
fuged for 30 min at 400 × g at room temperature. The light-
density, mononuclear cell (MNC) layer was harvested and
washed twice in Iscove's modified Dulbecco's medium + 2%
FBS, then washed once in PBS containing 2% FBS. Another
complete blood count with automated differential was then
performed to determine the MNC count.
Flow cytometric analysis of hematopoietic stem cell 
populations
We measured the currently recognized, standard populations
of hematopoietic progenitor and stem cells (that is, the CD34+
cells and CD34+CD38- cells) by flow cytometry; in addition,
the CD34+c-kit+ stem/progenitor population was also quanti-
tated by this method. Umbilical cord-derived MNC (see above)
were adjusted to a concentration of 1 × 106 cells in 50 μl PBS
containing 2% FBS and were incubated with the following
fluorochrome-conjugated antibodies (all from BD Biosciences
Pharmingen, San Diego, CA, USA) for 30 minutes on ice, in
the dark: anti-CD34-fluorescein isothiocyanate (FITC), anti-
CD38-phycoerythrin, anti-c-kit-phycoerythrin, or the combina-
tion of anti-CD34-FITC and anti-CD38-phycoerythrin, or the
combination of anti-CD34-FITC and anti-c-kit-phycoerythrin.
Samples treated with mouse IgG-phycoerythrin and IgG-FITC,
or no antibody, served as controls.
The treated cells were washed once with PBS, centrifuged,
and then resuspended in 50 μl of 4% paraformaldehyde. After
an overnight incubation at 4°C in the dark, the cell suspension
was brought up to 400 μl in PBS and was analyzed using a
multi-laser flow cytometer (FACSCalibur™; BD Biosciences
Immunocytometry Systems, San Jose, CA, USA) at the Univer-
sity of Massachusetts Medical School Flow Cytometry Core
Facility. Quality control of the flow cytometric analyses was
performed on the BD Biosciences FACSCalibur™ on a daily
basis. Particles of known fluorescent characteristics (Calbrite
particles; BD Biosciences) were utilized to examine instrument
alignment and sensitivity. Instrument daily quality control val-
ues were maintained and stored by the Flow Cytometry Core
Facility staff. The CD34+, CD34+CD38-, and CD34+c-kit+
hematopoietic progenitor populations were quantitated from
the gated MNC population (lymphocytes and monocytes,
based on forward versus side light scatter) using the FlowJo™
software program (Tree Star, Inc., Ashland, OR, USA); back-
gating demonstrated that all stem/progenitor subpopulations
were within the gated MNC population. These progenitor pop-
ulations were then normalized to 103 MNC counts and the val-
ues used in statistical analyses.
These three independently assayed stem/progenitor subpop-
ulations were determined to be highly correlated to one
another: Spearman correlation coefficients relating CD34+/
103 MNC levels to CD34+CD38-/103 MNC levels and
CD34+c-kit+/103 MNC levels were 0.86 (P < 0.0001) and
0.93 (P < 0.0001), respectively, and the Spearman correlation
coefficient relating CD34+CD38-/103 MNC levels to CD34+c-
kit+/103 MNC levels was 0.88 (P < 0.0001).
Analysis of hematopoietic stem cell potential by GM-
CFU assay
Primitive hematopoietic progenitor cells have the ability to form
colonies in vitro in semisolid medium upon stimulation with
specific growth factors. The growth of colonies derived from
GM-CFU in semisolid medium characterizes the proliferative
potential of stem cells [17] and is used here for verifying the
results from flow cytometry. We have used GM-CFU colony
formation in methylcellulose-based semisolid medium as a
measurement of stem/progenitor populations within the cord
blood samples. Cord blood MNC (2 × 104 cells) or CD34+
cells (3 × 102 cells, isolated from the MNC population using
the EasySep™ immunomagnetic cell enrichment system; Stem
Cell Technologies) were plated in 35-mm tissue culture plates
containing 1.1 ml methylcellulose medium (MethoCult™ GF
H4534; Stem Cell Technologies). Plates were incubated at
37°C in a 95% air:5% CO2 humidified atmosphere and colo-
nies consisting of 40 cells or greater were quantitated after 14
days using an Olympus model SZ-ILA stereo microscope.
Based on a mean of GM-CFU counts from four plates, results
were expressed as the number of GM-CFU/103 MNC. GM-
CFU values were highly correlated to the FACS-based stem/
progenitor measurements, with Spearman correlation coeffi-
cients relating GM-CFU/103 MNC values (n = 175) to
CD34+/103 MNC, CD34+CD38-/103 MNC, and CD34+c-kit+/
103 MNC of 0.88 (P < 0.0001), 0.76 (P < 0.0001), and 0.84
(P < 0.0001), respectively.
Hormone assays
Hormone levels in the umbilical cord plasma samples were
assayed at the ILAT Steroid RIA Laboratory, Department of
Physiology, University of Massachusetts Medical School.
Estradiol and testosterone were measured by radioimmu-
noassay using kits from Diagnostic Products Corporation (Los
Angeles, CA, USA). The inter-assay coefficients of variation
were 6.8% and 8.9%, and the intra-assay coefficients of vari-
ation were 3.4% and 5.6%, respectively. Unconjugated estriol,
progesterone, prolactin, and SHBG were measured using
chemiluminescent immunoassays from Diagnostic Products
Corporation. The inter-assay coefficients of variation were
9.2%, 7.9%, 6.4%, and 4.8%, respectively, and the intra-assay
coefficients of variation were 6.6%, 6.3%, 5.7%, and 2.0%,
respectively. IGF-1 and IGFBP-3 were measured by immuno-
radiometric assay using IMMULITE (an automated method
from Diagnostic Products Corporation), with inter-assay coef-
ficients of variation of 9.0% and 8.0%, respectively, and intra-
assay coefficients of variation of 3.3% and 4.8%, respectively.
The quality control coefficients of variation were calculated
using internal control samples included with each assay.
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Statistical analysis
Descriptive statistics on the characteristics of study popula-
tion and laboratory data were calculated. Spearman rank cor-
relation coefficients were estimated for bivariate analyses.
Multivariate linear regression was used to examine the associ-
ation between hormones (independent variable) and natural
log-transformed measures of stem cell potential (dependent
variable), adjusting for maternal and neonatal characteristics
(mother's age, race of parents, number of live births, gestation
duration, baby's gender and birth weight, delivery time, and
study site). Maternal age, gestational duration, and birth
weight were treated as continuous variables. The fitted coeffi-
cients from the regression analyses were exponentiated to
obtain the estimated proportional change in outcome associ-
ated with each independent variable. Statistical significance
was set at 0.05 (two-sided). To conduct statistical analyses,
the SAS program (version 9.1; SAS Institute, Cary, NC, USA)
was used.
Results
Maternal and newborn characteristics, cord blood hormone
levels, and cord blood cell populations of the total samples (n
= 289) are presented in Table 1. With the exception of ethnic-
ity, the maternal and newborn characteristics, including
mother's age and education levels, gestation period, time and
method of delivery, and infant's birth weight, were similar
between the Worcester-derived samples and the Boston-
derived samples (data not shown). The Boston cord blood
samples had higher GM-CFU concentrations (5.4 ± 3.2 colo-
nies/103 MNC) than the previously reported Worcester sam-
ples (0.84 ± 0.47 colonies/103 MNC), but this was due to a
methodological change in which cells were plated in a more
efficacious commercial growth medium for obtaining GM-
CFUs.
The correlation of the cord blood plasma levels of the eight-
factor panel of sex hormones, growth factors, and their asso-
ciated binding proteins with measurements of stem cell poten-
tial of the umbilical cord samples (that is, CD34+,
CD34+CD38-, and CD34+c-kit+ pools and GM-CFU values,
all expressed per 103 cord blood MNC) was then assessed by
bivariate analysis. As shown in Table 2, Spearman correlation
coefficients between IGF-1 cord blood plasma levels and all
four quantitations of stem and progenitor populations were
highly significant (coefficients ranging from 0.18 to 0.21). The
correlation of IGFBP-3 with these stem/progenitor popula-
tions was less strong, with significant correlations only
between this protein level and the CD34+ and CD34+c-kit+
subpopulations. Cord blood plasma estriol levels correlated
significantly with the concentrations of the more primitive
hematopoietic stem cell pools (that is, the CD34+CD38- and
CD34+c-kit+ populations). Interestingly, the cord plasma levels
of the SHBG, representing a potential negative regulator of
sex hormone action, were found to be negatively correlated to
each measurement of stem/progenitor potential (Spearman
correlation coefficients of -0.12 to -0.16).
Multiple linear regression analysis was then performed on
these data to take into account potential confounding factors
involving maternal and neonatal variables including mother's
age, race of parents, number of live births, gestation duration,
delivery time, birth weight, offspring gender, and study site
(Table 3). IGF-1 levels remained strongly associated with all
cord blood stem/progenitor concentrations, with each stand-
ard-deviation increase in IGF-1 being associated with a 15–
19% increase in stem/progenitor concentrations. IGFBP-3
levels were again positively correlated to CD34+ and CD34+c-
kit+ pools, and estriol levels to CD34+CD38- and CD34+c-kit+
pools, with a one standard-deviation increase in estriol being
associated with an 11–12% increase in the concentration of
these populations. By this analysis, SHBG remains negatively
correlated to these stem/progenitor populations, but only the
association with CD34+ pools was statistically significant.
Different racial and ethnic groups in the United States have dif-
fering rates of breast cancer [18]. We explored whether the
correlations between cord blood plasma levels of growth fac-
tors and hormones and concentration of hematopoietic stem
cells would hold across various racial and ethnic groups. We
divided the data by racial/ethnic categories, and bivariate anal-
ysis was repeated. As shown in Table 4, cord blood plasma
levels of IGF-1 are positively and significantly correlated with
all four measurements of stem/progenitor cell populations in
the Caucasian subgroup, which represent the majority of sam-
ples (147 of 252 with known ethnicity). IGF-1 levels are also
significantly correlated with some stem/progenitor measure-
ments (CD34+ and CD34+c-kit+ pools) in the Hispanic-Amer-
ican subgroup (n = 15), but not in the African-American (n =
20), Asian-American (n = 39), or mixed (n = 31) subgroups.
Similarly, cord blood plasma estriol levels are positively corre-
lated with stem cell pools in the Caucasian subgroup, but not
in any of the other subgroups (Table 4). Estradiol levels are
positively and significantly correlated only to the CD34+c-kit+
in Caucasians and to the CD34+CD38- in Hispanic-Ameri-
cans, but not in other racial/ethnic groups. Finally, SHBG was
negatively but significantly correlated with some of the stem/
progenitor concentrations in the Caucasian samples but, for
the most part, not in the other subgroups.
Discussion
The stem cell burden theory provides a mechanistic framework
for understanding a number of epidemiological findings,
including that high birth weight can be linked with breast can-
cer risk [2] and risk in other cancer sites [3-5]; that levels of
certain mitogens (for example, IGF-1) are linked with both birth
weight [19] and breast cancer risk [20]; and, finally, that mam-
mographic breast density (mammary gland area per unit breast
area), a correlate of breast tissue cell number [21], prenatal
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Table 1
Summary of the maternal and newborn characteristics, cord blood hormone levels, and cord blood cell populations
Variable n Meana Range
Subject characteristics
Mother's age (years) 289 30.0 ± 5.5 18.0–43.0
Race/ethnicity of mother and biological father
Both Caucasian 147 (58.33%)
Both African-American 20 (7.94%)
Both Asian 39 (15.48%)
Both Hispanic 15 (5.95%)
Mixed 31 (12.30%)
No data 37
Parity
First 118 (43.54%)
Second 77 (28.41%)
Third 46 (16.97%)
Fourth and above 30 (11.07%)
No data 18
Prepregnancy weight (kg) 199 62.7 ± 12.3 38.3–112.5
Gestation duration (weeks) 289 39.6 ± 1.2 36.5–44.0
Gender of the baby
Male 134 (50.57%)
Female 131 (49.43%)
No data 24
Birth weight (g) 288 3,402.4 ± 431.9 2,256–4,660
Cord blood volume (ml) 289 92.5 ± 24.6 44.5–201.5
Cord blood plasma hormone levels
Estradiol (ng/dl) 289 930.9 ± 528.6 40.6–3,305.4
Unconjugated estriol (ng/ml) 289 331.0 ± 141.4 18.1–1,459.5
Testosterone (ng/ml) 289 1.7 ± 0.9 0.3–9.2
Sex hormone-binding globulin (nmol/l) 289 22.8 ± 8.0 6.7–55.0
Progesterone (ng/ml) 289 226.6 ± 134.4 26.5–841.0
Prolactin (ng/ml) 289 254.0 ± 103.6 47.4–686.0
Insulin-like growth factor-1 (ng/ml) 289 81.2 ± 52.5 10.2–306.7
Insulin-like growth factor binding protein-3 (ng/ml) 289 941.1 ± 309.9 300.0–2,534.0
Cord blood cell populations
Initial total nucleated cells × 106/ml 288b 16.1 ± 5.2 6.3–40.6
Initial mononuclear cells × 106/ml 288b 7.6 ± 2.8 2.8–20.8
CD34+ cells/103 mononuclear cells 289 8.9 ± 5.5 0.4–35.5
CD34+CD38- cells/103 mononuclear cells 289 4.1 ± 2.7 0.0–14.4
CD34+c-kit+ cells/103 mononuclear cellsc 249 7.6 ± 4.9 0.2–34.4
Granulocyte–macrophage colony-forming units/103 mononuclear cellsd 175 5.4 ± 3.2 0.5–19.7
aData presented as mean ± standard deviation or mean (%). bInitial total nucleated cells/ml and mononuclear cells/ml values not determined in 
one sample. cOnly samples from the Tufts–New England Medical Center were assayed. dData only from Tufts–New England Medical Center-
derived samples, due to a change in assay method.
Breast Cancer Research    Vol 9 No 3    Savarese et al.
Page 6 of 10
(page number not for citation purposes)
and perinatal factors [22] and, speculatively, breast stem cell
number and activity [10], is a strong predictor of breast cancer
risk [23] and has been associated with both IGF-1 serum lev-
els [24] and birth weight [22].
Ethical and practical considerations preclude a direct testing
of this hypothesis (that is, establishing whether or not there is
an association between prenatal mitogens and breast stem
cell quantities) in humans. As an indirect approach, we have
used measurements of hematopoietic stem cell and progeni-
tor cell concentrations in readily accessible umbilical cord
blood samples as surrogates for general stem cell activity or
'stem cell potential'. Although hematopoietic stem cells are
capable of giving rise to a wide range of nonhematopoietic
cells [9], there has been no report on a direct link with breast
stem cells. Levels of hematopoietic stem cells were therefore
used in this study as proxy indicators of stem cell burden to
correlate with cord blood plasma levels of endocrine factors,
which represent the in utero concentrations of these factors.
A pilot study indicated that cord blood plasma levels of IGF-1,
its major binding protein IGFBP-3, and to a lesser degree
estriol are positively correlated with hematopoietic stem/pro-
genitor concentrations [16]. This finding provided the first evi-
dence linking perinatal growth factor and hormone levels to
stem cell potential. In the present large study (289 samples),
we document more firmly that cord blood plasma levels of IGF-
1 are strongly correlated to all cord blood stem and progenitor
concentrations examined, and that IGFBP-3 and estriol are
positively correlated to at least some of these stem/progenitor
measurements.
The results with respect to IGF-1 are not surprising, as there
is considerable evidence that IGF-1 is a positive effector of
hematopoiesis. This evidence includes the following: adding
IGF-1 to in vitro cultures of CD34+ or CD34+CD38- precur-
sors augments their proliferation in response to standard col-
ony-stimulating factors such as GM-CSF, granulocyte colony-
stimulating factor and IL-3 [25], in part by acting as an antiap-
optotic factor [26]; in vivo, IGF-1 or the physiologic inducer of
IGF-1, growth hormone, can stimulate erythropoieisis, myelo-
poieisis and granulopoiesis in hypophysectomized or myelo-
suppressed rodent model systems [27,28]; and, thirdly,
growth hormone administered to patients with growth
hormone deficiency coelevates IGF-1 levels and erythroid and
myeloid progenitors [29].
There is less evidence linking IGFBP-3 levels with hematopoi-
esis. Recently, however, recombinant IGFBP-3 was shown to
directly stimulate the proliferation of human CD34+CD38-
hematopoietic precursors in the absence of IGF-1 [30].
Furthermore, IGFBP-3 is one of the factors elaborated by
embryonic stromal feeder-layer cells that can support hemat-
opoietic stem cell growth [31]. Why estriol levels correlate
with cord blood hematopoietic stem/progenitor concentra-
tions is less clear, although estrogens have been used in con-
junction with other growth factors to stimulate the ex vivo
proliferation of erythroid precursors from avian bone marrow
[32] and human cord blood [33].
Table 2
Spearman correlation coefficients (P values) between cord blood sex hormones, growth factors, and associated binding proteins 
and cord blood hematopoietic progenitor/stem cell populations
Hormone/binding 
protein
Total nucleated 
cells/ml
Mononuclear 
cells/ml
Measures of stem cell potential, counts/103 mononuclear cells
CD34+ (n = 289) CD34+CD38- (n = 
289)
CD34+c-kit+ (n = 
249)a
Granulocyte–
macrophage 
colony-forming 
units (n = 175)b
Estradiol 0.14 (0.02) 0.15 (0.01) 0.05 (0.37) 0.02 (0.79) 0.06 (0.36) 0.03 (0.67)
Estriol 0.20 (0.0006) 0.15 (0.01) 0.09 (0.14) 0.14 (0.02) 0.15 (0.02) 0.11 (0.16)
Testosterone 0.19 (0.001) 0.13 (0.03) -0.03 (0.60) 0.01 (0.80) 0.02 (0.80) 0.06 (0.41)
Sex hormone-
binding globulin
0.003 (0.96) 0.05 (0.36) -0.12 (0.04) -0.13 (0.03) -0.13 (0.03) -0.16 (0.04)
Progesterone 0.15 (0.009) 0.15 (0.01) -0.01 (0.84) -0.04 (0.50) -0.008 (0.90) -0.009 (0.91)
Prolactin 0.27 (<0.0001) 0.21 (0.0004) -0.005 (0.93) 0.02 (0.70) 0.09 (0.17) 0.01 (0.90)
Insulin-like growth 
factor-1
-0.05 (0.41) -0.09 (0.14) 0.18 (0.002) 0.19 (0.001) 0.21 (0.001) 0.18 (0.02)
Insulin-like growth 
factor binding 
protein-3
0.10 (0.10) 0.08 (0.20) 0.14 (0.01) 0.11 (0.07) 0.12 (0.05) 0.11 (0.14)
aDetermined only in the Tufts–New England Medical Center-derived samples. bData only from the Tufts–New England Medical Center-derived 
samples.
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The more relevant question in terms of the stem cell burden
theory of breast cancer risk is whether IGF-1 and/or estrogen
levels correlate with breast stem cell pool expansion. Although
this question cannot be directly answered, it is apparent that
both IGF-1 and estrogens are critical to the primitive mammary
epithelium during development. In mouse knockout models,
IGF-1 null mice have a sharply decreased formation of mam-
mary terminal end buds and ductal branching [34], as do
estrogen receptor alpha (ERα) null mice [35]. In sexually
immature female rats that have been hypophysectomized (to
eliminate the endogenous growth hormone/IGF-1 axis) and
oophorectomized (to remove the major endogenous source of
estrogens), treatment with IGF-1 and estradiol were synergis-
tic for restoring full mammary gland development [36]; similar
results were obtained in IGF-1 null mice [37]. It is reasonable
to assume that a factor such as IGF-1 is acting on primitive
breast stem and progenitor cells to drive these developmental
changes.
Whether or not estrogens act directly on breast stem cells,
however, is less clear. At present it is not known whether the
most primitive breast stem cells are ERα- and give rise to more
committed ERα+ cells, or vice versa. Murine mammary stem
cells lack ERα, progesterone receptor, and erbB2 [38]. This
pattern is the same as that found in the so-called 'basal' type
of breast cancer, a subclass of breast cancer. Based on micro-
array gene expression analysis, this subclass of breast cancer
possesses a relatively undifferentiated, stem-like expression
profile [39]. In addition, cell culture methods for isolating and
expanding breast epithelial precursor cells often do not utilize
estrogen. On the other hand, human mammary epithelial cells
with stem-like properties isolated from adult tissues are ERα+
[40], and long-lived, slow cycling, ERα+ cells, have been
described in mouse mammary tissue [41]. Alternatively, a pop-
ulation of ERα+ cells in the developing mammary gland might
serve a paracrine function for adjacent ERα- stem/progenitors.
This would explain the synergy of estrogens and IGF-1 in
mammary development even if breast stem cells lack ERα
[42].
Finally, our data suggest that race/ethnicity may modify the
correlations between in utero/perinatal levels of factors such
as IGF-1 and estrogens and stem cell values. The associations
between cord blood plasma levels of IGF-1, IGFBP-3, or
estrogens and cord blood hematopoietic stem cell values
were stronger in the Caucasian and Hispanic subgroups and
were weaker or not present in the Asian-American and African-
American subgroups. Comparatively low sample numbers for
the latter three subgroups preclude making a definitive conclu-
sion on this issue. Caucasians tended to rank high among the
groups in terms of hematopoietic stem cell values, whereas
Hispanic-Americans ranked low, but again these differences
among the subgroups were not significant (data not shown).
Other investigators have reported that cord blood from Cau-
casians contain relatively high hematopoietic stem cell con-
centrations among racial/ethnic groups [43]. Also, since the
Asian-American group had the highest levels of estriol (data
not shown), it is possible that the nonsignificant relations
reflect the lowered study power to document associations
within populations at the high or low ends of the hormone lev-
els. Factors underlying these racial/ethnic differences in sign-
Table 3
Multiple linear regression analysisa for the association between measurements of hematopoietic stem cell populations and 
umbilical cord blood plasma levels of hormones and associated binding proteins
Hormone/binding protein CD34+ cells/103 mononuclear 
cells
CD34+ CD38-/103 mononuclear 
cells
CD34+c-kit+/103 mononuclear 
cellsb
Granulocyte–macrophage 
colony-forming units/103 
mononuclear cellsc
% changed (95% 
confidence interval)
P value % change (95% 
confidence interval)
P value % change (95% 
confidence interval)
P value % change (95% 
confidence interval)
P value
Estradiol 3.8 (-4.6, 13.0) 0.39 3.0 (-6.1, 13.0) 0.52 6.6 (-4.4, 18.9) 0.25 2.6 (-8.9, 15.6) 0.67
Estriol 7.5 (-2.6, 18.6) 0.15 11.1 (-0.1, 23.6) 0.05 12.9 (0.8, 26.5) 0.04 10.4 (-3.0, 25.7) 0.13
Testosterone 0.2 (-7.4, 8.5) 0.95 2.1 (-6.3, 11.3) 0.63 2.3 (-6.3, 11.6) 0.62 0.2 (-8.4, 9.5) 0.97
Sex hormone-binding 
globulin
-7.9 (-15.3, 0.1) 0.05 -7.4 (-15.5, 1.5) 0.10 -8.3 (-17.0, 1.2) 0.09 -6.6 (-16.2, 4.1) 0.21
Progesterone -0.2 (-8.3, 8.7) 0.97 -1.9 (-10.6, 7.6) 0.69 -0.9 (-9.9, 9.1) 0.86 0.8 (-10.1, 13.0) 0.90
Prolactin -0.4 (-8.4, 8.4) 0.93 1.3 (-7.6, 11.0) 0.78 5.3 (-4.6, 16.1) 0.30 4.8 (-6.3, 17.2) 0.41
Insulin-like growth factor-1 17.3 (7.2, 28.4) 0.001 16.4 (5.5, 28.5) 0.003 19.2 (7.7, 32.0) 0.001 15.1 (2.6, 29.1) 0.02
Insulin-like growth factor 
binding protein-3
10.8 (1.3, 21.3) 0.03 8.1 (-2.1, 19.3) 0.12 10.9 (0.02, 23.0) 0.05 9.7 (-2.3, 23.0) 0.12
aFrom multiple regression model, adjusting for mother's age, race of parents (both Caucasian or not), number of live births, gestation duration, 
gender of baby, and delivery time (day or night). The study site (American Red Cross or Tufts–New England Medical Center) was also adjusted in 
the analysis of the pooled samples. bDetermined only in the Tufts–New England Medical Center-derived samples (n = 249). cData only from the 
Tufts–New England Medical Center-derived samples (n = 175). d% change, expected proportional change in dependent variable associated with 
one standard-deviation increase per independent variable.
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aling molecule/stem cell correlations and breast cancer risk
itself will require further study.
Conclusion
Cord blood levels of IGF-1 are strongly positively associated
with concentrations of all the cord blood stem and progenitor
cells examined. IGFBP-3 and estriol levels are positively asso-
ciated with at least some of these cell populations, whereas
SHBG tends to show inverse associations with these popula-
tions. Our data therefore support the hypothesis that intrauter-
ine levels of breast epithelial mitogens modulate stem/
progenitor pools and could, thus, affect long-term risk of
breast and perhaps other forms of cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TMS oversaw the laboratory research protocols and drafted
the manuscript. WCS participated in the design of study pro-
tocol and collected patient samples and questionnaire infor-
mation. HPL participated in the stem cell experiments and
conducted analyses on flow cytometry data. QL participated in
the design of the study and performed the statistical analysis.
IB participated in the design of the questionnaire and coordi-
nated the study. WO oversaw the hormonal assays. DPC par-
ticipated in the design of clinical protocol and subject
enrollment. PL participated in the analyses and interpretation
of the results. PQ advised on the stem cell experiments and
participated in the interpretation of results. KLN oversaw the
clinical research protocols. C-CH conceived the study, partic-
ipated in the design, analysis, and result interpretation. All
authors read and approved the final manuscript.
Table 4
Spearman correlation coefficients (P values) between cord blood sex hormones, growth factors, and associated binding proteins 
and hematopoietic stem/progenitor cell populations among different racial/ethnic groups
Stem/progenitor cell 
measurement
Estradiol Estriol Testosterone Sex hormone-
binding globulin
Progesterone Prolactin Insulin-like 
growth factor-1
Insulin-like growth 
factor binding protein-3
Both parents Caucasian (n = 147)
CD34+/103 MNC 0.12 (0.16) 0.16 (0.06) -0.04 (0.59) -0.18 (0.03) -0.01 (0.87) -0.05 (0.52) 0.24 (0.003) 0.12 (0.15)
CD34+CD38-/103 MNC 0.13 (0.12) 0.25 (0.002) 0.05 (0.53) -0.16 (0.05) -0.02 (0.80) -0.02 (0.80) 0.23 (0.004) 0.05 (0.58)
CD34+c-kit+/103 MNC 0.21 (0.03) 0.30 (0.001) 0.05 (0.61) -0.17 (0.07) -0.001 (0.99) 0.10 (0.29) 0.26 (0.005) 0.09 (0.32)
GM-CFU/103 MNC 0.11 (0.32) 0.24 (0.03) 0.13 (0.24) -0.16 (0.16) -0.02 (0.88) 0.13 (0.25) 0.24 (0.03) 0.07 (0.56)
Both parents African-American (n = 20)
CD34+/103 MNC -0.25 (0.28) -0.27 (0.24) -0.22 (0.34) -0.33 (0.16) -0.14 (0.57) -0.23 (0.32) 0.09 (0.71) 0.19 (0.41)
CD34+CD38-/103 MNC -0.25 (0.28) 0.008 (0.97) -0.08 (0.75) -0.32 (0.18) -0.10 (0.67) -0.02 (0.93) -0.003 (0.99) 0.86 (0.72)
CD34+c-kit+/103 MNC -0.40 (0.09) -0.38 (0.11) -0.31 (0.19) -0.42 (0.07) -0.23 (0.34) -0.34 (0.15) 0.12 (0.63) 0.30 (0.20)
GM-CFU/103 MNC -0.39 (0.15) -0.40 (0.14) -0.25 (0.36) -0.52 (0.04) -0.42 (0.12) -0.13 (0.63) -0.02 (0.94) 0.35 (0.20)
Both parents Asian-American (n = 39)
CD34+/103 MNC 0.14 (0.38) 0.09 (0.58) 0.22 (0.19) 0.08 (0.65) 0.15 (0.37) 0.19 (0.25) 0.15 (0.36) 0.06 (0.73)
CD34+CD38-/103 MNC 0.14 (0.93) 0.07 (0.66) 0.17 (0.29) 0.03 (0.86) 0.08 (0.62) 0.14 (0.40) 0.15 (0.35) 0.004 (0.98)
CD34+c-kit+/103 MNC 0.13 (0.42) 0.10 (0.53) 0.19 (0.24) 0.08 (0.64) 0.15 (0.35) 0.19 (0.26) 0.16 (0.35) 0.05 (0.75)
GM-CFU/103 MNC 0.26 (0.25) 0.22 (0.33) 0.24 (0.30) 0.26 (0.26) 0.24 (0.29) 0.09 (0.71) 0.31 (0.17) 0.06 (0.78)
Both parents Hispanic-American (n = 15)
CD34+/103 MNC 0.45 (0.10) -0.16 (0.58) -0.38 (0.17) -0.04 (0.90) -0.06 (0.83) 0.14 (0.63) 0.51 (0.05) 0.01 (0.97)
CD34+CD38-/103 MNC 0.60 (0.02) 0.24 (0.40) 0.01 (0.96) -0.21 (0.45) 0.09 (0.76) 0.14 (0.61) 0.38 (0.16) -0.11 (0.70)
CD34+c-kit+/103 MNC 0.38 (0.19) -0.05 (0.86) -0.35 (0.22) -0.19 (0.51) 0.16 (0.57) 0.23 (0.44) 0.62 (0.02) 0.07 (0.82)
GM-CFU/103 MNC -0.01 (0.98) -0.47 (0.24) -0.49 (0.22) -0.46 (0.26) 0.22 (0.61) -0.25 (0.55) 0.25 (0.55) -0.20 (0.63)
Parents of differing ethnicity/race (mixed) (n = 31)
CD34+/103 MNC -0.06 (0.74) -0.14 (0.46) -0.03 (0.85) -0.07 (0.71) 0.009 (0.96) 0.21 (0.25) 0.03 (0.87) 0.05 (0.80)
CD34+CD38-/103 MNC -0.19 (0.32) -0.18 (0.32) -0.08 (0.68) -0.03 (0.86) -0.05 (0.79) 0.33 (0.07) 0.08 (0.65) 0.25 (0.18)
CD34+c-kit+/103 MNC 0.03 (0.87) 0.005 (0.98) -0.002 (0.99) -0.08 (0.68) 0.004 (0.98) 0.19 (0.31) -0.04 (0.83) -0.02 (0.93)
GM-CFU/103 MNC 0.19 (0.38) 0.23 (0.27) 0.24 (0.27) -0.20 (0.34) 0.20 (0.34) 0.01 (0.95) 0.11 (0.62) 0.08 (0.72)
Those correlation coefficients that are significant (P ≤ 0.05) are in boldface. GM-CSF, granulocyte–macrophage colony-forming units; MNC, 
mononuclear cells.
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